Utility of coronary revascularization in patients with ischemic left ventricular dysfunction

被引:0
作者
Al-Sadawi, Mohammed [1 ]
Tao, Michael [2 ]
Dhaliwal, Simrat [2 ]
Radakrishnan, Archanna [2 ]
Liu, Yang [2 ]
Gier, Chad [2 ]
Masson, Ravi [2 ]
Rahman, Tahmid [2 ]
Tam, Edlira [2 ]
Mann, Noelle [2 ]
机构
[1] Univ Michigan Hosp, Div Cardiol, Ann Arbor, MI USA
[2] Stony Brook Univ Hosp, Dept Med, Div Cardiol, Stony Brook, NY USA
关键词
Percutaneous coronary intervention; Revascularization; Ischemic cardiomyopathy; Severe left ventricular dysfunction; MYOCARDIAL VIABILITY ASSESSMENT; DOSE DOBUTAMINE ECHOCARDIOGRAPHY; ARTERY-BYPASS-SURGERY; LONG-TERM SURVIVAL; PROGNOSTIC VALUE; FOLLOW-UP; MAGNETIC-RESONANCE; EJECTION FRACTION; DISEASE; STRATEGIES;
D O I
10.1016/j.carrev.2024.02.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Revascularization in patients with left ventricular (LV) dysfunction has been a subject of ongoing uncertainty and conflicting results. This is further complicated by factors including viability, severity of LV dysfunction, and method of revascularization using percutaneous coronary intervention (PCI) versus coronary-artery bypass grafting (CABG). Objectives: The purpose of this meta-analysis is to evaluate the association of coronary revascularization with outcomes in patients with ischemic LV dysfunction. Methods: A literature search was conducted for studies reporting on cardiovascular outcomes after revascularization compared to optimal medical therapy (OMT) in patients with ischemic LV dysfunction. Results: A total of 23 studies with 10,110 participants met inclusion criteria. Revascularization was significantly associated with lower all-cause mortality and CV mortality compared to OMT. The association was statistically significant regardless of severity of LV dysfunction or method of revascularization. Subgroup analysis demonstrated that revascularization was significantly associated with lower all-cause and CV mortality compared to OMT for patients with viable myocardium and mixed cohorts with variable viability, but not patients without viable myocardium. Revascularization was not associated with a significant difference in risk of heart failure (HF) hospitalization or acute myocardial infarction (AMI) compared to OMT. Conclusions: Revascularization in patients with ischemic LV dysfunction is associated with lower risk of all-cause and CV mortality independent of severity of LV dysfunction or method of revascularization. Revascularization is not associated with lower risk of mortality in patients without evidence of viable myocardium and is not associated with lower risk of AMI or HF hospitalization.
引用
收藏
页码:88 / 97
页数:10
相关论文
共 50 条
  • [21] Left ventricular function recovery after revascularization: comparative effects of percutaneous coronary intervention and coronary artery bypass grafting
    Ngu, Janet M. C.
    Ruel, Marc
    Sun, Louise Y.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (06) : 633 - 637
  • [22] Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
    Bonow, Robert O.
    Maurer, Gerald
    Lee, Kerry L.
    Holly, Thomas A.
    Binkley, Philip F.
    Desvigne-Nickens, Patrice
    Drozdz, Jaroslaw
    Farsky, Pedro S.
    Feldman, Arthur M.
    Doenst, Torsten
    Michler, Robert E.
    Berman, Daniel S.
    Nicolau, Jose C.
    Pellikka, Patricia A.
    Wrobel, Krzysztof
    Alotti, Nasri
    Asch, Federico M.
    Favaloro, Liliana E.
    She, Lilin
    Velazquez, Eric J.
    Jones, Robert H.
    Panza, Julio A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (17) : 1617 - 1625
  • [23] Stable coronary artery disease and left ventricular dysfunction: The role of revascularization
    Aksut, Baran
    Starling, Randall
    Kapadia, Samir
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2017, 90 (05) : 777 - 783
  • [24] SURGICAL MYOCARDIAL REVASCULARIZATION OF PATIENTS WITH ISCHEMIC CARDIOMYOPATHY AND SEVERE LEFT VENTRICULAR DISFUNCTION
    Hovnanian, Andre L.
    Soeiro, Alexandre de Matos
    Serrano, Carlos Vicente, Jr.
    de Oliveira, Sergio Almeida
    Jatene, Fabio B.
    Stolf, Noedir A. G.
    Ramires, Jose A. F.
    CLINICS, 2010, 65 (01) : 3 - 8
  • [25] Revascularization in left ventricular dysfunction: an update
    Yanagawa, Bobby
    Lee, Jessica
    Puskas, John D.
    Verma, Subodh
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (05) : 536 - 542
  • [26] Real-World Outcomes of Revascularization Strategies in Patients With Left Ventricular Dysfunction and Three-Vessel Coronary Disease Stratified by Mitral Regurgitation
    Fan, Qin
    Liu, Jun
    Xu, Yan
    Ni, Ruiqing
    Xi, Rui
    Wang, Fang
    Hu, Jian
    Sun, Hongyue
    Yang, Zhenkun
    Zhou, Mi
    Zhang, Ruiyan
    Zhao, Qiang
    Tao, Rong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [27] Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction Do We Have the Evidence?
    Gulati, Rajiv
    Gersh, Bernard J.
    CIRCULATION, 2016, 133 (22) : 2125 - 2127
  • [28] Extreme Risk of Sudden Cardiac Death within Three Months after Revascularization in Patients with Ischemic Left Ventricular Systolic Dysfunction
    Wang, Shaoping
    Lyu, Yi
    Liu, Yanci
    Cheng, Shujuan
    Li, Shiying
    Zheng, Ze
    Gu, Xiaoyan
    Gong, Ming
    Liu, Jinghua
    Borah, Bijan J.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (10)
  • [29] Appropriate time for ejection fraction reassessment after revascularization in patients with left ventricular dysfunction for risk stratification of sudden cardiac death
    Wang, Shaoping
    Lyu, Yi
    Cheng, Shujuan
    Wu, Zheng
    Li, Shiying
    Zheng, Ze
    Gu, Xiaoyan
    Li, Jinhua
    Liu, Jinghua
    Borah, Bijan J.
    CLINICAL CARDIOLOGY, 2024, 47 (01)
  • [30] Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients with Left Ventricular Systolic Dysfunction
    Mahin R. Khan
    Waleed T. Kayani
    Jason Pelton
    Ahmed Ansari
    David Paniagua
    Umair Khalid
    Ali Denktas
    Hameem U. Changezi
    Ahmad Munir
    Ernesto Jimenez
    Mahboob Alam
    Hani Jneid
    Cardiovascular Drugs and Therapy, 2021, 35 : 575 - 585